Chey Tae-won, chairman of SK Group, had his eldest daughter, Chey Yoon-chung, head of business development at SK Biopharm, appointed as head of strategy to lead SK Biopharm's future growth.
SK Biopharm said on the 4th that it has carried out a 2026 organizational reshuffle.
The company said it is restructuring to proactively respond to the changing global business environment and to strengthen core functions and boost execution around future growth pillars.
Chey Yoon-chung, who has led the existing business development division, was appointed head of strategy. The strategy division plans to further strengthen the consistency and speed of executing future strategies by integrating the company's core decision-making functions, including companywide mid- to long-term strategy development, business portfolio management, global growth strategy promotion, and new business review.
To fully launch the radiopharmaceutical (RPT) business, which has emerged as a future growth modality, the company created a new RPT division.
The RPT division is an organization equipped with end-to-end operational functions, including securing raw materials and isotopes, discovering pipelines and conducting preclinical studies, and developing global business. With this new unit, the company made clear its intention to foster the RPT business as a core growth pillar.
SK Biopharm said it plans to further enhance its competitiveness in the global market through this organizational reshuffle and solidify the foundation for balanced growth in new drugs and new businesses. The organizational changes take effect Jan. 1 next year.